Fig. 6

DCLK1 is a promising target in mesenchymal-like subtype of TNBC. a, b High mRNA expression of DCLK1 (a) and IL-6 (b) predicts reduced recurrence-free survival (RFS) in TNBC (n = 392) subtype rather than Luminal A (n = 522), Luminal B (n = 332) or HER2 (n = 315) subtype according to KM-potter database. c High mRNA expression of DCLK1 and predicts reduced overall survival (OS) in TNBC tissues according to KM-plotter database (n = 153). d The boxplot showing a significantly higher expression of DCLK1 in the MES subtype than the other three subtypes. e Receiver operating characteristic (ROC) curve for using DCLK1 expression to identify the MES subtype. f CCK8 assays to determine the toxicity of DCLK1 inhibitor, DCLK1-IN-1, on TNBC cells. g CCK8 assays to determine the cell viability of mesenchymal-like cells BT549 and basal-like cells MDA-MB-468 with different treatment as indicated (left and middle), and the cells surviving different treatments were also showed by crystal violet (right). h Western blotting showing the effects of DCLK1-IN-1 on EMT and CSC-associated marker in BT549 cells. i Transwell assays showing the inhibited migratory/invasive abilities in BT549 cells treated with DCLK1-IN-1. j Tumor growth curves showing the anti-tumor effects after DCLK1-IN-1 or S31-201 treatment (left), tumors from the indicated treatments were removed and photographed (right). (n = 6 per group). k Excised tumor weights showing a significant decrease after DCLK1-IN-1 or S31-201 treatment. l Flow cytometry analyzing the percentage of CD8+ T cells in subcutaneous tumor tissues after the indicated treatments